IRVING, Texas and PALO ALTO, Calif., Nov.
18, 2015 /PRNewswire/ -- Caris Life Sciences®, a
leading biotechnology company focused on fulfilling the promise of
precision medicine, and Syapse, the leading provider of precision
medicine software, announced a collaboration to collect and combine
molecular and genomic information with clinical treatment and
outcomes data across the Caris Centers of Excellence for Precision
Medicine Network™ (COE Network). The COE Network consists of
leading cancer centers that have demonstrated a commitment to
precision medicine and are working collaboratively to establish
improved standards of care for molecular tumor profiling in
oncology. Integration of Caris Molecular Intelligence®, Caris'
panomic, comprehensive tumor profiling service, with the Syapse
Precision Medicine Platform℠, will provide a powerful real-time,
point-of-care, clinical decision support system to enable more
informed treatment decisions for each individual patient.
Participating COE Network sites can use the integrated decision
support system, and may use Syapse to further support their
complete precision medicine workflows.
The collaboration enables patient outcomes data to be combined
with the most comprehensive and clinically actionable molecular
profile available. Caris Molecular Intelligence uses multiple
technology platforms, including a proprietary 592-gene
Next-Generation Sequencing (NGS) panel with full gene coverage to
assess point mutations, indels, and copy number variations,
alongside RNAseq, for select gene fusions, in addition to
Immunohistochemistry (IHC), in situ Hybridization (ISH), and
other platforms. This comprehensive interrogation of DNA, RNA, and
protein expression enables Caris to include critical companion
diagnostics for biomarkers such as ALK, ROS, HER2 and PDL1, and to
provide associations for three key therapeutic classes: targeted
therapies, immunotherapies and chemotherapeutics.
"We expect to profile 50,000 to 100,000 cancer patients annually
across the COE Network. This is the largest oncology focused effort
to combine comprehensive genomic and molecular profiling
information with clinical outcomes data. It is sure to yield
powerful information that will change the future of personalized
medicine," said David D. Halbert,
Chairman and CEO of Caris Life Sciences. "We are excited to be
working closely with Syapse and to further support the work of the
Caris Centers of Excellence for Precision Medicine Network."
Under the agreement, Syapse software will be used to enable the
COE Network to develop a better understanding of cancer and the
most effective means of treatment and to provide patients with
better access to new therapies and clinical trials. Select COE
Network members will use Syapse to capture key oncology-specific
clinical data from electronic medical records, integrate clinical
data with Caris Molecular Intelligence tumor profiling results, and
aggregate de-identified data into Caris' centralized instance of
the Syapse Precision Medicine Platform for sharing across the COE
Network. In addition, Syapse will enable COE Network members to
participate in virtual tumor boards, where they can review cases,
capture guidance, and disseminate knowledge throughout the
Network.
"This collaboration gives participating COE Network members the
decision support, clinical workflow and data aggregation tools they
need to realize meaningful improvements in patient care," said
Jonathan Hirsch, President and
Founder of Syapse. "Sharing the clinical and molecular profile of
patients, alongside their treatments and outcomes, will enable
members of the COE Network to collaboratively develop the best
practices and clinical utility evidence needed to advance the
practice of precision oncology."
About Caris Life Sciences®
Caris Life Sciences® is a leading biotechnology company focused
on fulfilling the promise of precision medicine through quality and
innovation. Caris Molecular Intelligence®, the company's healthcare
information and comprehensive tumor profiling service with more
than 80,000 patients profiled, provides oncologists with the most
clinically actionable treatment options available to personalize
cancer care today. Using a variety of advanced profiling
technologies to assess relevant biological changes in each
patient's tumor, Caris Molecular Intelligence connects biomarker
data generated from a tumor with biomarker-drug associations
supported by evidence in the relevant clinical literature. Since
2009, Caris Life Sciences has tracked clinical and outcome data for
certain patients undergoing tumor profiling, and has observed that
patients treated with drugs consistent with their tumor profile
show a significant increase in overall survival. The company
is also developing its ADAPT Biotargeting System™, a revolutionary
and unbiased profiling platform with applications across therapy
development, drug delivery, advanced diagnostics and disease
monitoring. Currently being developed for cancer and other complex
diseases, the ADAPT Biotargeting System is able to simultaneously
measure millions of molecular interactions within complex
biological systems in their natural state(s). Headquartered in
Irving, Texas, Caris Life Sciences
offers services throughout the U.S., Europe, Australia and other international markets. To
learn more, please visit www.CarisLifeSciences.com.
About Syapse
Syapse software enables healthcare providers to deploy precision
medicine programs. Leading academic and community healthcare
providers use the Syapse Precision Medicine Platform to integrate
complex genomic and clinical data to provide clinicians with
actionable insights at point of care, enabling diagnosis,
treatment, and outcomes tracking. Headquartered in Palo Alto, California, Syapse is backed by The
Social+Capital Partnership and Safeguard Scientifics (NYSE: SFE).
For more information, visit www.syapse.com.
Media Inquiries for Caris Life Sciences:
Media Relations & Corporate Affairs
CorpComm@carisls.com
David Patti, JFK
Communications
dpatti@jfkhealth.com
609-456-0822
Media Inquiries for Syapse:
Jordan Stockton
jordan.stockton@syapse.com
650-924-1461
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/caris-life-sciences-and-syapse-collaborate-to-aggregate-oncology-data-that-will-power-precision-medicine-and-improve-patient-care-300180720.html
SOURCE Caris Life Sciences